CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	18.09	194.57	206.45	192.78	189.34
Short-Term Investments	157.34	0	99.7	124.26	107.72
Cash & Cash Equivalents	175.43	194.57	306.14	317.04	297.06
Cash Growth	-9.84%	-36.45%	-3.44%	6.72%	-32.03%
Receivables	3.43	35.99	0.79	0.8	0.01
Other Current Assets	4.08	6.55	3.37	6.18	6.26
Total Current Assets	182.94	237.1	310.3	324.01	303.34
Property, Plant & Equipment	16.18	21.02	25.32	29.45	32.75
Goodwill and Intangibles	1.68	1.82	1.97	2.12	2.26
Other Long-Term Assets	1	0.94	1.82	3.09	2.93
Total Long-Term Assets	18.86	23.79	29.11	34.65	37.95
Total Assets	201.79	260.89	339.41	358.66	341.28
Accounts Payable	1.46	2.81	2.82	3	4.16
Deferred Revenue	212.32	301.33	284.76	318.71	230.24
Current Debt	4.59	4.08	0	0	0
Other Current Liabilities	-62.45	-155.61	-209.71	-253.59	-148.81
Total Current Liabilities	155.91	152.61	77.87	68.11	85.59
Long-Term Debt	9.39	13.98	18.06	21.68	24.87
Other Long-Term Liabilities	83.94	180.06	243.94	276.65	179.71
Total Long-Term Liabilities	93.33	194.03	262	298.33	204.58
Total Liabilities	249.24	346.64	339.87	366.44	290.17
Total Debt	13.97	18.06	18.06	21.68	24.87
Debt Growth	-22.61%	0.01%	-16.70%	-12.85%	-
Retained Earnings	-723.45	-722.88	-623.56	-507.69	-417.23
Comprehensive Income	0.1	0.01	-0.24	-0.05	0.06
Shareholders' Equity	-47.45	-85.75	-0.46	-7.77	51.11
Net Cash / Debt	161.45	176.51	288.09	295.36	272.19
Net Cash / Debt Growth	-8.53%	-38.73%	-2.46%	8.51%	-37.72%
Net Cash Per Share	2.19	2.68	4.49	6.40	6.00
Working Capital	27.02	84.49	232.43	255.9	217.75
Book Value Per Share	-0.64	-1.30	-0.01	-0.17	1.13

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).